Person who experienced the adverse event (patient)
| Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 125266821 | 12526682 | 1 | I | 2001 | 20160621 | 20160705 | 20160705 | EXP | GB-SUN PHARMACEUTICAL INDUSTRIES LTD-2016RR-119598 | RANBAXY | 30.00 | YR | F | Y | 58.96000 | KG | 20160705 | OT | GB | GB |
Drug(s) used by person
| Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 125266821 | 12526682 | 1 | PS | VENLAFAXINE | VENLAFAXINE HYDROCHLORIDE | 1 | Oral | 225 MG, QD | N | U | 91272 | 225 | MG |
Indications of drugs used
| Event ID | CASEID | INDI DRUG SEQ | INDI PT |
|---|---|---|---|
| 125266821 | 12526682 | 1 | Depression |
Outcome of event
| Event ID | CASEID | OUTC COD |
|---|---|---|
| 125266821 | 12526682 | OT |
| 125266821 | 12526682 | DS |
Reactions reported
| Event ID | CASEID | DRUG REC ACT | PT |
|---|---|---|---|
| 125266821 | 12526682 | Abnormal behaviour | |
| 125266821 | 12526682 | Feeling abnormal | |
| 125266821 | 12526682 | Memory impairment | |
| 125266821 | 12526682 | Weight increased |
Reporting Sources (this data is often not reported and may therefore be missing here)
| no results found |
Therapies reported
| Event ID | CASEID | DSG DRUG SEQ | START DT | END DT | DUR | DUR COD |
|---|---|---|---|---|---|---|
| 125266821 | 12526682 | 1 | 2001 | 0 |